![]() |
Volumn 97, Issue 16, 2017, Pages 1252-1255
|
Clinical value of the early use of ulinastatin in patients with moderately severe or severe acute pancreatitis
|
Author keywords
Acute kidney injury; Acute respiratory distress syndrome; Pancreatitis; Shock; Ulinastatin
|
Indexed keywords
AMYLASE;
C REACTIVE PROTEIN;
INTERLEUKIN 6;
INTERLEUKIN 8;
SOMATOSTATIN;
TUMOR NECROSIS FACTOR;
ULINASTATIN;
GLYCOPROTEIN;
INTERLEUKIN DERIVATIVE;
TRYPSIN INHIBITOR;
ABDOMINAL PAIN;
ABDOMINAL PRESSURE;
ACUTE PANCREATITIS;
AMYLASE BLOOD LEVEL;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL STUDY;
COMPARATIVE EFFECTIVENESS;
CONTROLLED STUDY;
DEFECATION;
DISEASE SEVERITY;
DISEASE SEVERITY ASSESSMENT;
DOWN REGULATION;
DRUG EFFECT;
DRUG EFFICACY;
DRUG USE;
EARLY INTERVENTION;
HUMAN;
INCIDENCE;
INFLAMMATION;
INTENSIVE CARE UNIT;
LENGTH OF STAY;
LEUKOCYTE COUNT;
OBSERVATIONAL STUDY;
PROSPECTIVE STUDY;
PROTEIN BLOOD LEVEL;
RANDOMIZED CONTROLLED TRIAL;
UNIVERSITY HOSPITAL;
ACUTE DISEASE;
METABOLISM;
PANCREATITIS;
ACUTE DISEASE;
DOWN-REGULATION;
GLYCOPROTEINS;
HUMANS;
INTERLEUKIN-6;
INTERLEUKINS;
PANCREATITIS;
PROSPECTIVE STUDIES;
TRYPSIN INHIBITORS;
TUMOR NECROSIS FACTOR-ALPHA;
|
EID: 85020123692
PISSN: 03762491
EISSN: None
Source Type: Journal
DOI: 10.3760/cma.j.issn.0376-2491.2017.16.015 Document Type: Article |
Times cited : (7)
|
References (9)
|